Dose-limiting mucositis: friend or foe?
Dose-limiting toxicities
Mucositis
Pediatric oncology
Therapy de-escalations
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
07 Oct 2023
07 Oct 2023
Historique:
received:
10
05
2023
accepted:
02
10
2023
medline:
9
10
2023
pubmed:
7
10
2023
entrez:
7
10
2023
Statut:
epublish
Résumé
Dose-limiting toxicities are ubiquitous to cancer-directed therapy, presenting with severity to a degree that necessitates therapy de-escalation, pause, or discontinuation. To date, there is incredible limited understanding if these therapy de-escalations present risk for survival by limiting delivery of intensive therapy, or if they indicate physiologic susceptibility and are a favorable prognostic indicator. Mucositis is an excellent illustration of the current paradox of dose-limiting toxicities-it has existed alongside therapy for eight decades, but despite its presence, there is an incomplete understanding of how it develops, why it varies between oncologic populations, and if it relates to cancer survival. Rigorous methodologic approaches in symptom science holds potential to better understand mucositis, to determine if it is a marker of response or threat, and evaluate if it holds potential to guide therapy delivery.
Identifiants
pubmed: 37804322
doi: 10.1007/s00520-023-08101-x
pii: 10.1007/s00520-023-08101-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
617Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Collins M, Wilhelm M, Conyers R et al (2013) Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 31(18):2303–2312. https://doi.org/10.1200/jco.2012.43.8598
doi: 10.1200/jco.2012.43.8598
pubmed: 23669227
Fanning SR, Rybicki L, Kalaycio M et al (2006) Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 135(3):374–381. https://doi.org/10.1111/j.1365-2141.2006.06323.x
doi: 10.1111/j.1365-2141.2006.06323.x
pubmed: 16995885
Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Gajjar A, Packer RJ (2014) Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children’s Oncology Group. Pediatr Blood Cancer 61(1):102–106. https://doi.org/10.1002/pbc.24670
doi: 10.1002/pbc.24670
pubmed: 23956184
McTiernan A, Jinks RC, Sydes MR et al (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer 48(5):703–712. https://doi.org/10.1016/j.ejca.2011.09.012
doi: 10.1016/j.ejca.2011.09.012
pubmed: 22036088
pmcid: 3657154
Wong HH, Halford S (2015) Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol 16(13):1287–1288. https://doi.org/10.1016/S1470-2045(15)00248-X
doi: 10.1016/S1470-2045(15)00248-X
pubmed: 26433816
Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C (2021) Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer 21(1):60. https://doi.org/10.1186/s12885-021-07782-z
doi: 10.1186/s12885-021-07782-z
pubmed: 33441097
pmcid: 7805102
Miller TP, Marx MZ, Henchen C et al (2022) Challenges and barriers to adverse event reporting in clinical trials: a Children’s Oncology Group report. J Patient Saf 18(3):e672–e679. https://doi.org/10.1097/pts.0000000000000911
doi: 10.1097/pts.0000000000000911
pubmed: 34570002
pmcid: 8940729